CICatherine Ingels

Catherine Ingels

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Catherine Ingels has a total of 100 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Successful clinical transplantation of hearts donated after circulatory death using direct procurement followed by hypothermic oxygenated perfusion: A report of the first 3 cases

    by Janne Brouckaert, Katrien Vandendriessche, Karlien Degezelle, Kristof Van de Voorde, Francis De Burghgraeve, Lars Desmet, Dirk Vlasselaers, Catherine Ingels, Dieter Dauwe, Erwin De Troy, et al.


  • Open Access

    Lung Transplant Outcome From Selected Older Donors (≥70 Years) Equals Younger Donors (<70 Years)

    by Cedric Vanluyten, Christelle M. Vandervelde, Robin Vos, Jan Van Slambrouck, Steffen Fieuws, Paul De Leyn, Philippe Nafteux, Herbert Decaluwé, Hans Van Veer, Lieven Depypere, et al.

    Objective: To describe our experience with lung transplantation (LTx) from donors ≥70 years and compare short and long-term outcomes to a propensity-matched cohort of donors P = 0.85). Reintervention rate was comparable (29% vs 16%; P = 0.10). Follow-up bronchoscopy revealed no difference in bronchial anastomotic complications (P = 1.00). Five-year patient and chronic lung allograft dysfunction-free survivals were 73.6% versus 73.1% (P = 0.72) and 51.5% versus 59.2% (P = 0.41), respectively. Conclusions: LTx from selected donors ≥70 years is feasible and safe, yielding comparable short and long-term outcomes in a propensity-matched analysis with younger donors (<70 years).


  • We need to better recognise and value the contribution of nurses to end-of-life care (Bloomer, ICCN 2022)

    by Julie Benbenishty, Freda DeKeyser Ganz, Matthew H. Anstey, Francisco Jose Barbosa-Camacho, Maria Grazia Bocci, Elif Ayşe Çizmeci, Knut Dybwik, Catherine Ingels, Alexandre Lautrette, Roberto Carlos Miranda-Ackerman, et al.

  • Changes in intensive care unit nurse involvement in end of life decision making between 1999 and 2016: Descriptive comparative study

    by Julie Benbenishty, Freda DeKeyser Ganz, Matthew H. Anstey, Francisco Jose Barbosa-Camacho, Maria Grazia Bocci, Elif Ayşe Çizmeci, Knut Dybwik, Catherine Ingels, Alexandre Lautrette, Roberto Carlos Miranda-Ackerman, et al.


  • Open Access

    Impact of anastomosis time during lung transplantation on primary graft dysfunction

    by Christelle M. Vandervelde, Robin Vos, Cedric Vanluyten, Steffen Fieuws, Stijn E. Verleden, Jan Van Slambrouck, Paul De Leyn, Willy Coosemans, Philippe Nafteux, Herbert Decaluwé, et al.


  • C-reactive protein rise in response to macronutrient deficit early in critical illness: sign of inflammation or mediator of infection prevention and recovery

    by Catherine Ingels, Lies Langouche, Jasperina Dubois, Inge Derese, Sarah Vander Perre, Pieter J. Wouters, Jan Gunst, Michaël Casaer, Fabian Güiza, Ilse Vanhorebeek, et al.

    Purpose Withholding parenteral nutrition (PN) early in critical illness, late-PN, has shown to prevent infections despite a higher peak C-reactive protein (CRP). We investigated whether the accentuated CRP rise was caused by a systemic inflammatory effect mediated by cytokines or arose as a consequence of the different feeding regimens, and whether it related to improved outcome with late-PN. Methods This secondary analysis of the EPaNIC-RCT first investigated, with multivariable linear regression analyses, determinants of late-PN-induced CRP rise and its association with cytokine responses (IL-6, IL-10, TNF-α) in matched early-PN and late-PN patients requiring intensive care for ≥ 3 days. Secondly, with multivariable logistic regression and Cox proportional-hazard analyses, we investigated whether late-PN-induced CRP rises mediated infection prevention and enhanced recovery or reflected an adverse effect counteracting such benefits of late-PN. Results CRP peaked on day 3, higher with late-PN [216(152–274)mg/l] (n = 946) than with early-PN [181(122–239)mg/l] (n = 946) (p < 0.0001). Independent determinants of higher CRP rise were lower carbohydrate and protein intakes (p ≤ 0.04) with late-PN, besides higher blood glucose and serum insulin concentrations (p ≤ 0.01). Late-PN did not affect cytokines. Higher CRP rises were independently associated with more infections and lower likelihood of early ICU discharge (p ≤ 0.002), and the effect size of late-PN versus early-PN on these outcomes was increased rather than reduced after adjusting for CRP rise, not confirming a mediating role. Conclusions The higher CRP rise with late-PN, explained by the early macronutrient deficits, did not relate to cytokine responses and thus did not reflect more systemic inflammation. Instead of mediating clinical benefit on infection or recovery, the accentuated CRP rise appeared an adverse effect reducing such late-PN benefits.


  • Effect of Intravenous 25OHD Supplementation on Bone Turnover and Inflammation in Prolonged Critically Ill Patients

    by Catherine Ingels, Ilse Vanhorebeek, Sophie Van Cromphaut, Pieter J. Wouters, Inge Derese, Alexander Dehouwer, Holger Jon Møller, Troels K. Hansen, Jaak Billen, Chantal Mathieu, et al.

    Critically ill patients have low circulating 25-hydroxyvitamin D (25OHD), vitamin D binding protein (DBP), and 1,25-dihydroxyvitamin D [1,25(OH)2D]. Low 25OHD is associated with poor outcomes, possibly explained by its effect on bone and immunity. In this prospective, randomized double-blind, placebo-controlled study, we investigated the feasibility of normalizing 25OHD in prolonged (>10 days) critically ill patients and the effects thereof on 1,25(OH)2D, bone metabolism, and innate immunity. Twenty-four patients were included and compared with 24 matched healthy subjects. Patients were randomized to either intravenous bolus of 200 μg 25OHD followed by daily infusion of 15 μg 25OHD for 10 days, or to placebo. Parameters of vitamin D, bone and mineral metabolism, and innate immune function were measured. As safety endpoints, ICU length of stay and mortality were registered. Infusion of 25OHD resulted in a sustained increase of serum 25OHD (from median baseline 9.2 –16.1 ng/ml at day 10), which, however, remained below normal levels. There was no increase in serum 1,25(OH)2D but a slight increase in serum 24,25(OH)2D. Mineral homeostasis, innate immunity and clinical safety endpoints were unaffected. Thus, intravenous 25OHD administration during critical illness increased serum 25OHD concentrations, though less than expected from data in healthy subjects, which suggests illness-induced alterations in 25OHD metabolism and/or increased 25OHD distribution volume. The increased serum 25OHD concentrations were not followed by a rise in 1,25(OH)2D nor were bone metabolism or innate immunity affected, which suggests that low 25OHD and 1,25OHD levels are part of the adaptive response to critical illness.


  • Open Access

    Leukocyte telomere length in paediatric critical illness: effect of early parenteral nutrition

    by Sören Verstraete, Ilse Vanhorebeek, Esther van Puffelen, Inge Derese, Catherine Ingels, Sascha C. Verbruggen, Pieter J. Wouters, Koen F. Joosten, Jan Hanot, Gonzalo G. Guerra, et al.

    Children who have suffered from critical illnesses that required treatment in a paediatric intensive care unit (PICU) have long-term physical and neurodevelopmental impairments. The mechanisms underlying this legacy remain largely unknown. In patients suffering from chronic diseases hallmarked by inflammation and oxidative stress, poor long-term outcome has been associated with shorter telomeres. Shortened telomeres have also been reported to result from excessive food consumption and/or unhealthy nutrition. We investigated whether critically ill children admitted to the PICU have shorter-than-normal telomeres, and whether early parenteral nutrition (PN) independently affects telomere length when adjusting for known determinants of telomere length. Telomere length was quantified in leukocyte DNA from 342 healthy children and from 1148 patients who had been enrolled in the multicenter, randomised controlled trial (RCT), PEPaNIC. These patients were randomly allocated to initiation of PN within 24 h (early PN) or to withholding PN for one week in PICU (late PN). The impact of early PN versus late PN on the change in telomere length from the first to last PICU-day was investigated with multivariable linear regression analyses. Leukocyte telomeres were 6% shorter than normal upon PICU admission (median 1.625 (IQR 1.446–1.825) telomere/single-copy-gene ratio (T/S) units vs. 1.727 (1.547–1.915) T/S-units in healthy children (P < 0.0001)). Adjusted for potential baseline determinants and leukocyte composition, early PN was associated with telomere shortening during PICU stay as compared with late PN (estimate early versus late PN –0.021 T/S-units, 95% CI −0.038; 0.004, P = 0.01). Other independent determinants of telomere length identified in this model were age, gender, baseline telomere length and fraction of neutrophils in the sample from which the DNA was extracted. Telomere shortening with early PN was independent of post-randomisation factors affected by early PN, including longer length of PICU stay, larger amounts of insulin and higher risk of infection. Shorter than normal leukocyte telomeres are present in critically ill children admitted to the PICU. Early initiation of PN further shortened telomeres, an effect that was independent of other determinants. Whether such telomere-shortening predisposes to long-term consequences of paediatric critical illness should be further investigated in a prospective follow-up study. ClinicalTrials.gov, NCT01536275 . Registered on 16 February 2012.


  • Soluble RAGE and the RAGE Ligands HMGB1 and S100A12 in Critical Illness

    by Catherine Ingels, Inge Derese, Pieter J. Wouters, Greet Van Den Berghe, Ilse Vanhorebeek

    Systemic inflammation often leads to complications in critically ill patients. Activation of the receptor for advanced glycation end-products (RAGE) generates inflammatory cytokines, proteases, and oxidative stress and may link inflammation to subsequent organ damage. Furthermore, hyperglycemia-induced oxidative stress increases RAGE ligands and RAGE expression. We hypothesized that preventing hyperglycemia during critical illness reduces the risk of excessively enhanced RAGE signaling, which could relate to clinical outcomes and risk of death. In 405 long-stay surgical intensive care unit patients randomized to intensive or conventional insulin treatment, serum concentrations of soluble RAGE (decoy receptor) and the RAGE ligands high-mobility group box 1 (HMGB1) and S100A12 were measured on admission, day 7, and last day. These were compared with levels in 71 matched control subjects and with C-reactive protein (CRP) as a routinely monitored inflammation marker. On admission, soluble RAGE, HMGB1, S100A12, and CRP were higher in patients than in controls. The HMGB1, S100A12, and CRP remained elevated throughout intensive care unit stay, whereas soluble RAGE decreased to levels lower than in controls by day 7. Unexpectedly, insulin treatment did not affect the circulating levels of these markers. In univariable analysis, elevated levels of soluble RAGE on admission were associated with adverse outcome, including circulatory failure, kidney failure, liver dysfunction, and mortality. The associations with circulatory and kidney failure remained significant in multivariable logistic regression analysis corrected for baseline risk factors. Critical illness affects components of RAGE signaling, unaffected by insulin treatment. Elevated on-admission soluble RAGE was associated with adverse outcomes.


  • Early Versus Late Parenteral Nutrition in Critically Ill Adults

    by Michael P. Casaer, Dieter Mesotten, Greet Hermans, Pieter J. Wouters, Miet Schetz, Geert Meyfroidt, Sophie van Cromphaut, Catherine Ingels, Philippe Meersseman, Jan Muller, et al.